Halozyme Therapeutics, Inc. (HALO)
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative biologic and drug delivery technologies. They are known for their enzyme-based platforms that enhance the absorption and distribution of therapeutic proteins and peptides, supporting the development of targeted cancer treatments, autoimmune disorders, and other medical conditions. The company's proprietary enzyme, ENHANZE, is used in collaborations with major pharmaceutical companies to improve the efficacy and administration of various biologics.
Company News
A Phase 1b/2 study of subcutaneous amivantamab in recurrent or metastatic head and neck cancer demonstrated a 45% overall response rate, with rapid and durable tumor responses in patients who had previously progressed on checkpoint inhibitors and chemotherapy.
Halozyme Therapeutics reported strong Q2 2025 financial results, with non-GAAP EPS of $1.54 (69% YoY growth) and revenue of $325.7 million (41% YoY increase). The company raised full-year guidance and continues to leverage its ENHANZE drug delivery technology through pharmaceutical partnerships.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. JP Morgan analyst Matthew Boss downgraded the rating for Vail Resorts, Inc. (NYSE:MTN) from Neutral to Underweight, while cutting the price targ...